// App-Quantinova.ai

TPS3096 : A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.

Researchers

Presenter

  • Johanna C. Bendell

Principal Investigators

  • Vijay Reddy

  • Fatemeh Tavakkoli

  • Ching Ching Leow

  • Xia Li

  • Rakesh Kumar

  • John H. Strickler

Medical Centers

  • Sarah Cannon Research Institute, Nashville, TN

  • MedImmune, Gaithersburg, MD

  • MedImmune, Gaithersburg, MD

  • Duke University Medical Center, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Durvalumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Fixed Dose

  • Open Label

  • Multicenteric

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02503774

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved